Spectrum Pharmaceutical’s CEO Rajesh Shrotriya, M.D presented an overview of the company today in Las Vegas at the Noble Financial Conference. I wanted to view the presentation in order to see if I could get additional information that may have been overlooked during my previous reviews of this company. For those of you who haven’t [...]

Let’s continue with our analysis of Spectrum Pharmaceuticals (SPPI), specifically reviewing their pipeline of drugs in development for readers that are interested in biotech stock investing.
Levoleucovorin (Fusilev):
Fusilev was approved in March 2008 as rescue therapy for osteosarcoma patients after receiving high-dose methotrexate (chemotherapy). Osteosarcoma is a malignant bone cancer afflicting individuals under the age of [...]

Spectrum Pharmaceuticals (SPPI) is a small cap biotech company that focuses on developing drugs in oncology and urology. Spectrum fits my investment criteria and warrants a thorough analysis. The company currently trades at a technology value (see previous posts on tech value) lower than any company I’ve come across over the past 8 years. In [...]